Stock Ratings / Health Care / PCRX / earnings

ANAB (61) GHRS (58) TYRA (41) AAPG (57) ⌘ Pro Terminal →

Pacira BioSciences Inc. (PCRX) Next Earnings Date & Expected ±1.8% Move

$36.39 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Pacira BioSciences Inc. (PCRX) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $1.45B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PCRX)Realized 20D OHLCV Swing Band: ±1.8%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±1.8% Swing Band

±$0.66 Expected Swing

MODEL EARNINGS SETUP GAUGE

PCRX Quantitative Pre-Earnings Setup: 54/100

Trailing EPS: $4.25 • YoY Revenue Growth: 3.6%

Model Bullish Setup (54/100)Model Risk Weight (46/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$726.4M	$7.0M	$136.7M	79.4%
FY 2024	2024-12-31	$701.0M	-$99.6M	$178.8M	75.7%
FY 2023	2023-12-31	$675.0M	$42.0M	$154.6M	79.4%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PCRX)

✓Walkthrough of PCRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PCRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +42.76%▲ ASCENDING CHANNEL

2026-10-30O $36.40H $36.43L $36.38C $36.39VOL 737.2K

RES: $37.96SUP: $23.91SMA50: $29.06SMA200: $24.84

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PCRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PCRX Butterfly Map → + Track PCRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

43.5%/yr Implied 5Y Growth

vs. +3.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PCRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PCRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PCRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PCRX)

Health Care Rank #292 of 1016 ⚔️ ANAB vs PCRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PCRX vs. ANAB, GHRS, TYRA, AAPG)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Pacira BioSciences Inc. (PCRX) ranks #292 by composite RQD confidence (54/100, grade D+) and #308 by equity capitalization ($1.45B). Within this direct 5-issuer industry benchmark cohort, PCRX leads on earnings valuation at N/A trailing P/E, while ANAB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. ANAB currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with PCRX at 54/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PCRX ACTIVE Pacira BioSciences Inc.	D+	54/100	—	79.4%	1.7%	0.00%	$1.45B	Benchmark Subject
ANAB AnaptysBio Inc.	C-	61/100	—	—	85.0%	-3.68%	$1.44B	/anab-vs-pcrx →
GHRS GH Research PLC	D+	58/100	—	—	—	+3.82%	$1.47B	/ghrs-vs-pcrx →
TYRA Tyra Biosciences Inc.	D-	41/100	—	—	-35.0%	-1.24%	$1.48B	/tyra-vs-pcrx →
AAPG Ascentage Pharma Group International American Depository Shares	D+	57/100	—	—	—	-0.70%	$1.39B	/aapg-vs-pcrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001396814

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pacira BioSciences Inc. (PCRX) reported GAAP revenue of $726.4M (+3.6% vs. FY2024 revenue of $701.0M , and +7.6% cumulative change since FY2023) , GAAP net income of $7.0M, operating cash flow of $152.0M, and free cash flow of $136.7M (-23.5% YoY). On the balance sheet, PCRX closed FY2025 with $1.26B in total assets against $372.2M in total debt (Altman Z-Score: 2.33, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$726.4M	$7.0M	$152.0M	$136.7M	$1.26B	$372.2M
FY2024 (FY)	2024-12-31	$701.0M	-$99.6M	$189.4M	$178.8M	$1.55B	$383.5M
FY2023 (FY)	2023-12-31	$675.0M	$42.0M	$154.6M	$154.6M	—	—

3. PCRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PCRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Pacira BioSciences Inc. (NASDAQ: PCRX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $36.39 (0.00% 1D, market cap $1.45B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, PCRX ranks #292 in composite RQD confidence.

How does PCRX compare to ANAB and GHRS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PCRX carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of 79.4%, and ROIC of 1.7%. By comparison, ANAB (AnaptysBio Inc.) holds a C- grade (61/100 RQD, P/E N/A, ROIC 85.0%, cap $1.44B) and GHRS (GH Research PLC) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $1.47B). Among the 5-stock peer group, PCRX leads on earnings multiple (N/A) while ANAB leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PCRX?

Per PCRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001396814), Pacira BioSciences Inc. generated $726.4M in revenue (+3.6% YoY), $7.0M in net income, and $136.7M in free cash flow against $1.26B in total assets and $372.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PCRX trading relative to its 50-day, 200-day, and 52-week technical levels?

PCRX last traded at $36.39 (0.00% on volume of 618,971 shares), positioning the stock +25.22% above its 50-day simple moving average ($29.06) and +46.50% above its 200-day simple moving average ($24.84). Across its 52-week range of $18.80 to $36.67, PCRX sits at the 98.4% percentile with a 14-day RSI of 83.2 (OVERBOUGHT (>70)) and an implied next-earnings move of ±1.8% ($35.73 to $37.05).